一项评估不良事件、疾病活动性变化以及静脉和皮下 Risankizumab 如何在患有中度至重度活动性克罗恩病的儿科参与者体内移动的研究 (RISE)
一项 3 期、多中心研究,通过开放标签诱导、随机双盲维持和长期延长期在儿童受试者(2 至 < 18 岁)中评估 Risankizumab 的药代动力学、疗效和安全性中度至重度活动性克罗恩病
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:ABBVIE CALL CENTER
- 电话号码:844-663-3742
- 邮箱:abbvieclinicaltrials@abbvie.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100045
- 招聘中
- Beijing Children's Hospital /ID# 256081
-
Beijing、Beijing Municipality、中国、100191
- 招聘中
- Peking University Third Hospital /ID# 255876
-
接触:
- Site Coordinator
- 电话号码:+86 010-82266699
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510620
- 招聘中
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
-
Guangzhou、Guangdong、中国、510655
- 招聘中
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
-
-
Henan
-
Zhengzhou、Henan、中国、450018
- 招聘中
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
-
-
Hunan
-
Changsha、Hunan、中国、410007
- 招聘中
- Hunan Children's Hospital /ID# 255610
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- 招聘中
- Jiangxi Provincial Children's Hospital /ID# 255564
-
-
Liaoning
-
Shenyang、Liaoning、中国、110022
- 招聘中
- Shengjing Hospital of China Medical University /ID# 255563
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200062
- 招聘中
- Children's Hospital of Shanghai /ID# 255531
-
Shanghai、Shanghai Municipality、中国、200065
- 招聘中
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
-
-
-
-
Central District
-
Petah Tikva、Central District、以色列、4920235
- 招聘中
- Schneider Children's Medical Center /ID# 254950
-
-
Jerusalem
-
Jerusalem、Jerusalem、以色列、91031
- 招聘中
- Shaare Zedek Medical Center /ID# 254951
-
-
-
-
-
Plovdiv、保加利亚、4002
- 招聘中
- UMHAT Sveti Georgi EAD /ID# 255386
-
Sofia、保加利亚、1606
- 完全的
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
-
Varna、保加利亚、9009
- 招聘中
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
-
-
-
-
Alberta
-
Calgary、Alberta、加拿大、T3B 6A8
- 招聘中
- Alberta Children's Hospital /ID# 255357
-
Edmonton、Alberta、加拿大、T6G 1C9
- 招聘中
- Edmonton Clinic Health Academy /ID# 255361
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V6H 3V4
- 招聘中
- BC Children's Hospital /ID# 255359
-
-
Ontario
-
London、Ontario、加拿大、N6A 5W9
- 招聘中
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
-
-
-
-
-
Changhua City, Changhua County、台湾、50006
- 招聘中
- Changhua Christian Hospital /ID# 256082
-
Taipei、台湾、100
- 招聘中
- National Taiwan University Hospital /ID# 255679
-
-
-
-
-
Ankara、土耳其(türkiye)、06560
- 招聘中
- Gazi University Medical Faculty /ID# 255086
-
Istanbul、土耳其(türkiye)、34453
- 招聘中
- Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
-
Istanbul、土耳其(türkiye)、34899
- 招聘中
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
-
Kocaeli、土耳其(türkiye)、41380
- 招聘中
- Kocaeli University Med Faculty /ID# 256922
-
-
-
-
Bavaria
-
Munich、Bavaria、德国、80337
- 招聘中
- Dr. von Haunerschen Kinderspital /ID# 255577
-
-
North Rhine-Westphalia
-
Münster、North Rhine-Westphalia、德国、48149
- 招聘中
- Universitaetsklinikum Muenster /ID# 256762
-
-
-
-
-
Messina、意大利、98125
- 招聘中
- Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
-
-
Genova
-
Genoa、Genova、意大利、16147
- 招聘中
- IRCCS Istituto Giannina Gaslini /ID# 255262
-
-
Napoli
-
Naples、Napoli、意大利、80131
- 招聘中
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
-
-
Roma
-
Rome、Roma、意大利、00165
- 招聘中
- Ospedale Pediatrico Bambino Gesu /ID# 255043
-
-
-
-
Praha 17
-
Prague、Praha 17、捷克语、128 00
- 完全的
- Vseobecna Fakultni nemocnice v Praze /ID# 256096
-
-
Praha 5
-
Prague、Praha 5、捷克语、150 06
- 完全的
- Fakultni nemocnice Motol a Homolka /ID# 256547
-
-
-
-
Aichi-ken
-
Ōbu、Aichi-ken、日本、474-8710
- 招聘中
- Aichi Children's Health And Medical Center /ID# 272085
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-0871
- 招聘中
- Tsujinaka Hospital - Kashiwanoha /ID# 268409
-
-
Fukuoka
-
Kurume-shi、Fukuoka、日本、830-0011
- 招聘中
- Kurume University Hospital /ID# 268418
-
-
Gunma
-
Maebashi、Gunma、日本、371-8511
- 招聘中
- Gunma University Hospital /ID# 270560
-
-
Kumamoto
-
Kumamoto、Kumamoto、日本、861-8520
- 招聘中
- Japanese Red Cross Kumamoto Hospital /ID# 268586
-
-
Osaka
-
Izumi-Shi、Osaka、日本、594-1101
- 招聘中
- Osaka Women's and Children's Hospital /ID# 268419
-
-
Saitama
-
Saitama-shi、Saitama、日本、330-8777
- 招聘中
- Saitama Children's Medical Center /ID# 268410
-
-
Tokyo
-
Bunkyo-ku、Tokyo、日本、113-8519
- 招聘中
- Institute of Science Tokyo Hospital /ID# 269175
-
Fuchu-shi、Tokyo、日本、183-8561
- 招聘中
- Tokyo Metropolitan Children's Medical Center /ID# 268415
-
Setagaya City、Tokyo、日本、157-8535
- 招聘中
- National Center For Child Health And Development /ID# 268420
-
-
-
-
-
Brussels、比利时、1020
- 招聘中
- Hospital Universite Enfants Reine Fabiola /ID# 255112
-
Liège、比利时、4000
- 招聘中
- Groupe Sante CHC - Clinique du MontLegia /ID# 255620
-
-
Antwerpen
-
Edegem、Antwerpen、比利时、2650
- 招聘中
- Uza /Id# 255114
-
-
Brussels Capital
-
Brussels、Brussels Capital、比利时、1200
- 招聘中
- Cliniques Universitaires UCL Saint-Luc /ID# 255108
-
Jette、Brussels Capital、比利时、1090
- 招聘中
- Universitair Ziekenhuis Brussel /ID# 255109
-
-
Vlaams-Brabant
-
Leuven、Vlaams-Brabant、比利时、3000
- 招聘中
- Universitair Ziekenhuis Leuven /ID# 255098
-
-
-
-
-
Paris、法国、75015
- 招聘中
- AP-HP - Hopital Necker /ID# 255608
-
-
Centre-Val de Loire
-
Tours、Centre-Val de Loire、法国、37044
- 招聘中
- CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
-
-
New Aquitaine
-
Bordeaux、New Aquitaine、法国、33076
- 招聘中
- Chu Bordeaux - Hopital Pellegrin /ID# 257060
-
-
Occitanie
-
Toulouse、Occitanie、法国、31059
- 招聘中
- CHU Toulouse - Hopital Paule de Viguier /ID# 255609
-
-
Rhone
-
Bron、Rhone、法国、69500
- 招聘中
- Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Torun、Kuyavian-Pomeranian Voivodeship、波兰、87-100
- 完全的
- Gastromed Sp. z o.o /ID# 255939
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、波兰、04-730
- 招聘中
- Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
-
-
-
-
-
Dorado、波多黎各、00646
- 招聘中
- Puerto Rico Health Institute /ID# 255071
-
San Juan、波多黎各、00909-1711
- 招聘中
- Clinical Research Puerto Rico /ID# 266479
-
-
-
-
Stockholm County
-
Stockholm、Stockholm County、瑞典、118 83
- 招聘中
- Sodersjukhuset /ID# 255239
-
Stockholm、Stockholm County、瑞典、171 76
- 招聘中
- Astrid Lindgrens Barnsjukhus /ID# 255240
-
-
Västra Götaland County
-
Gothenburg、Västra Götaland County、瑞典、413 46
- 招聘中
- Sahlgrenska Universitetssjukhuset /ID# 255236
-
接触:
- Site Coordinator
- 电话号码:+46313435865
-
-
-
-
-
Bern、瑞士、3010
- 招聘中
- Inselspital, Universitaetsspital Bern /ID# 255321
-
-
Canton of Zurich
-
Zurich、Canton of Zurich、瑞士、8032
- 招聘中
- Kinderspital Zurich - Eleonorenstiftung /ID# 255337
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85016-7710
- 招聘中
- Phoenix Children's Hospital /ID# 255766
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202
- 完全的
- Arkansas Children's Hospital /ID# 255762
-
-
California
-
Oakland、California、美国、94609
- 招聘中
- UCSF Benioff Children's Hospital - Oakland /ID# 258327
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- Children's Hospital Colorado - Aurora /ID# 255764
-
-
Florida
-
Orlando、Florida、美国、32806-1141
- 招聘中
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Indiana University Health Riley Hospital for Children /ID# 256454
-
-
Massachusetts
-
Waltham、Massachusetts、美国、02451
- 招聘中
- Massachusetts General Hospital - Mass General Waltham /ID# 255767
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55413-2195
- 招聘中
- MNGI Digestive Health, P. A. /ID# 255366
-
-
New Jersey
-
Morristown、New Jersey、美国、07960
- 招聘中
- Goryeb Childrens Hospital /ID# 256452
-
-
New York
-
New York、New York、美国、10029
- 招聘中
- Icahn School of Medicine at Mount Sinai /ID# 254880
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic - Cleveland /ID# 256453
-
接触:
- Site Coordinator
- 电话号码:216-636-2007
-
-
-
-
-
Birmingham、英国、B4 6NH
- 招聘中
- Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
-
-
England
-
Sheffield、England、英国、S10 2TH
- 招聘中
- Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
-
接触:
- Site Coordinator
- 电话号码:+44 114 273 0522
-
-
Greater London
-
London、Greater London、英国、E1 2ES
- 招聘中
- Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
-
-
-
-
North Holland
-
Amsterdam、North Holland、荷兰、1105 AZ
- 招聘中
- Amsterdam University Medical Center /ID# 254827
-
-
-
-
-
Madrid、西班牙、28009
- 完全的
- Hospital Infantil Universitario Nino Jesus /ID# 255012
-
Málaga、西班牙、29011
- 招聘中
- Hospital Regional Universitario de Malaga /ID# 257553
-
-
A Coruna
-
Ferrol、A Coruna、西班牙、15405
- 招聘中
- Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
-
-
-
-
-
Daegu、韩国、41404
- 招聘中
- Kyungpook National University Chilgok Hospital /ID# 255817
-
-
Seoul Teugbyeolsi
-
Seoul、Seoul Teugbyeolsi、韩国、03080
- 招聘中
- Seoul National University Hospital /ID# 255318
-
Seoul、Seoul Teugbyeolsi、韩国、06351
- 招聘中
- Samsung Medical Center /ID# 255284
-
Seoul、Seoul Teugbyeolsi、韩国、03722
- 招聘中
- Yonsei University Health System - Severance Hospital /ID# 256976
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria:
-
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
-
Any of the following medical disorders:
-
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
-
A diagnosis of CD prior to 2 years of age.
-
A diagnosis or suspected diagnosis of a primary immunodeficiency.
-
Currently known complications of CD such as:
- Active abscess (abdominal or perianal);
- Symptomatic bowel strictures;
- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
- Fulminant colitis;
- Toxic megacolon;
- Or any other manifestation that might require surgery while enrolled in the study.
-
Ostomy or ileoanal pouch.
-
Diagnosis of short gut or short bowel syndrome.
-
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
-
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
|
实验性的:Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
其他名称:
Subcutaneous (SC) Injection
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
大体时间:At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
大体时间:At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
大体时间:Up to approximately Week 64
|
Cmax of risankizumab |
Up to approximately Week 64
|
|
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
大体时间:Up to approximately 64 weeks
|
Tmax of risankizumab |
Up to approximately 64 weeks
|
|
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
大体时间:Up to approximately 64 weeks
|
AUCtau of risankizumab |
Up to approximately 64 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
大体时间:At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
大体时间:At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
大体时间:At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
大体时间:At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
大体时间:At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
大体时间:At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
大体时间:At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
大体时间:At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
大体时间:At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
大体时间:At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
大体时间:At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
大体时间:At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- M16-194
- 2022-502050-14-00 (其他标识符:EU CT)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共享时间框架
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD 共享访问标准
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.